Biotest Aktiengesellschaft (BIO) Stock Price, News & Analysis

0.00 (0.00%)
(As of 05/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
100 shs
Average Volume
1,927 shs
Market Capitalization
$823.26 million
P/E Ratio
Dividend Yield
Price Target
BIO stock logo

About Biotest Aktiengesellschaft Stock (ETR:BIO)

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infection; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, including neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B immunoglobulins. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols, S.A.

BIO Stock Price History

BIO Stock News Headlines

Biotest Aktiengesellschaft (BIOD.XC)
Biotest AG's Net Worth
Biotest AG Pfd.
EQS-Adhoc: Biotest AG: Erhöhung der EBIT Prognose
EQS-Adhoc: Biotest AG: Increase of the EBIT guidance
Biotest AG Pfd Shs - Non-voting
Hangzhou Biotest Biotech Co Ltd (688767)
Hangzhou Biotest Biotech Co. Ltd. A
Biotest Aktiengesellschaft (BIO3.DE)
DGAP-Adhoc: Biotest AG: Biotest exceeds Revenue guidance 2021
Biotest AG: Reduction of guidance
DGAP-Adhoc: Biotest AG: Reduction of guidance
Grifols, S.A. (GRFS)
See More Headlines
Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biotest Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Year Founded


Net Income
$127 million
Pretax Margin


Sales & Book Value

Annual Sales
$684.60 million
Cash Flow
€1.34 per share
Book Value
€12.61 per share


Free Float
Market Cap
$823.26 million
Not Optionable
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Peter Janssen (Age 56)
    CEO & Chairman of the Board of Management
    Comp: $764k
  • Ms. Ainhoa Mendizabal Zubiaga (Age 51)
    Member of Management Board & CFO
    Comp: $570k
  • Dr. Jorg Schuttrumpf (Age 50)
    Chief Scientific Officer & Member of the Management Board
    Comp: $523k
  • Dirk Schuck (Age 46)
    Member of Supervisory Board
  • Dr. Monika Buttkereit
    Head of Investor Relations
  • Dr. Christina Erb
    Head of Corporate HR

BIO Stock Analysis - Frequently Asked Questions

How have BIO shares performed in 2024?

Biotest Aktiengesellschaft's stock was trading at €42.60 on January 1st, 2024. Since then, BIO stock has decreased by 2.3% and is now trading at €41.60.
View the best growth stocks for 2024 here

Is Biotest Aktiengesellschaft a good dividend stock?

Biotest Aktiengesellschaft (ETR:BIO) pays an annual dividend of €0.04 per share and currently has a dividend yield of 0.18%. The dividend payout ratio is 1.25%. This payout ratio is at a healthy, sustainable level, below 75%.

What other stocks do shareholders of Biotest Aktiengesellschaft own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biotest Aktiengesellschaft investors own include Grifols (GRFS), CSL (CSL), BioXcel Therapeutics (BTAI) and ADMA Biologics (ADMA).

This page (ETR:BIO) was last updated on 5/20/2024 by Staff

From Our Partners